



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

**Clinical Updates for
Nurse Practitioners and
Physician Assistants: 2012/2013**



**December 1, 2012
Hyatt Fairfax at Fair Lakes
Fairfax, VA**

Course Directors
Deborah Paschal, CRNP
Gregg Sherman, MD

Activity Director
Michelle Frisch, MPH, CCMEP

Program Evaluation
December 13, 2012

In December 2012, the National Association for Continuing Education (NACE) sponsored a CE activity, *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Fairfax, VA.

This educational activity was designed to provide nurse practitioners and physician assistants the opportunity to learn about Osteoporosis, Psoriasis, Inflammatory Bowel Disease, Diabetes, Opioid Analgesics, and Atrial Fibrillation.

In planning this CE activity, NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Fifty one healthcare practitioners registered to attend *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Fairfax, VA. Twenty six healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Twenty five completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.


Physician assistants may receive a maximum of 6.5 hours of Category 1 credit for completing this program.

This program is approved for 6.5 contact hours of continuing education (which includes 5.5 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1210364

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	0	0.00	0.00
DO	0	0.00	0.00
NP	16	64.00	64.00
PA	9	36.00	36.00
RN	0	0.00	0.00
Other	0	0.00	0.00
Total Valid	25	100.00	100.00




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	18	72.00	72.00
Endocrinology	0	0.00	0.00
Rheumatology	0	0.00	0.00
Pulmonology	0	0.00	0.00
Cardiology	0	0.00	0.00
Gastroenterology	0	0.00	0.00
OB/GYN	0	0.00	0.00
Other	7	28.00	28.00
Total Valid	25	100.00	100.00




Upon completion of this activity, I can now - Identify appropriate candidates for BMD testing incorporating the FRAX 10-year fracture risk into treatment decisions; initiate pharmacologic therapy for patients who meet NOF guideline recommendations for pharmacologic management; implement education for dietary and supplemental calcium and vitamin D and exercises to prevent osteoporosis and related fractures; and recognize and overcome barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid Percent
Yes	24	96.00	100.00
Somewhat	0	0.00	0.00
Not at all	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




Upon completion of this activity, I can now - Explain the current pathophysiologic mechanisms associated with the development of psoriatic disease; discuss the impact of psoriatic disease including its effects on mood, cardiovascular risk, quality of life, and other co-morbid conditions; recognize the percent of body surface area that categorizes a patient for topical or systemic therapy; and implement appropriate treatment plans for patients who are candidates for topical and/or systemic therapy:

Label	Frequency	Percent	Valid Percent
Yes	22	88.00	91.67
Somewhat	2	8.00	8.33
Not at all	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and nonpharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; and use currently available laboratory tests to maximize benefit while minimizing toxicity:

Label	Frequency	Percent	Valid Percent
Yes	19	76.00	79.17
Somewhat	5	20.00	20.83
Not at all	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




Upon completion of this activity, I can now - Discuss the extent of abuse, misuse, addiction and diversion of opioid analgesics in the community; describe an approach to monitor and document a patient's progress with opioid therapy; implement strategies for early recognition and management of opioid abuse, misuse, addiction and diversion; understand opioid pharmacology and the use of analgesic equivalency tables:

Label	Frequency	Percent	Valid Percent
Yes	19	76.00	82.61
Somewhat	4	16.00	17.39
Not at all	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




Upon completion of this activity, I can now - Discuss the role of the incretin system in the pathophysiology of type 2 diabetes (T2DM); define the role of GLP-1 receptor agonist therapy in the treatment algorithm for T2DM; identify the features, benefits, and limitations of individual GLP-1 agonists; discuss the appropriate selection of GLP-1 receptor agonist therapy according to the glycemic disturbance most in need of correction:

Label	Frequency	Percent	Valid Percent
Yes	15	60.00	68.18
Somewhat	7	28.00	31.82
Not at all	0	0.00	0.00
Total Valid	22	88.00	100.00
Total Missing	3	12.00	
Total	25	100.00	




Upon completion of this activity, I can now - Use of the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify safe and effective use of new and emerging antithrombotic therapy for AF patients related to the risk stratification for stroke; and identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation:

Label	Frequency	Percent	Valid Percent
Yes	18	72.00	100.00
Somewhat	0	0.00	0.00
Not at all	0	0.00	0.00
Total Valid	18	72.00	100.00
Total Missing	7	28.00	
Total	25	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	13	52.00	54.17
Very Good	11	44.00	45.83
Good	0	0.00	0.00
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	13	52.00	54.17
Agree	11	44.00	45.83
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	14	56.00	58.33
Agree	10	40.00	41.67
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	13	52.00	54.17
Agree	11	44.00	45.83
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	13	52.00	56.52
Somewhat likely	8	32.00	34.78
Unlikely	0	0.00	0.00
Not applicable	2	8.00	8.70
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	14	56.00	60.87
1-3 months	5	20.00	21.74
4-6 months	1	4.00	4.35
Not applicable	3	12.00	13.04
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Sandra Hall Kesner, CNP (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	20	80.00	86.96
Very Good	3	12.00	13.04
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	16	64.00	69.57
Very Good	4	16.00	17.39
Good	2	8.00	8.70
Fair	0	0.00	0.00
Unsatisfactory	1	4.00	4.35
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Mark Osterman, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	16	64.00	69.57
Very Good	6	24.00	26.09
Good	1	4.00	4.35
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Carol P. Curtiss, MSN (Opioids):

Label	Frequency	Percent	Valid Percent
Excellent	20	80.00	86.96
Very Good	2	8.00	8.70
Good	1	4.00	4.35
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brenda Blyler, MSN, CRNP (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	3	12.00	15.79
Very Good	5	20.00	26.32
Good	7	28.00	36.84
Fair	4	16.00	21.05
Unsatisfactory	0	0.00	0.00
Total Valid	19	76.00	100.00
Total Missing	6	24.00	
Total	25	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: William Matthai, Jr., MD (AFib):


Label	Frequency	Percent	Valid Percent
Excellent	13	52.00	81.25
Very Good	3	12.00	18.75
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	16	64.00	100.00
Total Missing	9	36.00	
Total	25	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Sandra Hall Kesner, CNP (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	22	88.00	95.65
Very Good	1	4.00	4.35
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	


Sandra Hall Kesner CNP {Osteo} Bias



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brad P. Glick, DO (Psoriasis):


Label	Frequency	Percent	Valid Percent
Excellent	20	80.00	86.96
Very Good	3	12.00	13.04
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	

Brad P Glick DO {Psoriasis} Bias




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Mark Osterman, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	21	84.00	91.30
Very Good	2	8.00	8.70
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Carol P. Curtiss, MSN (Opioids):

Label	Frequency	Percent	Valid Percent
Excellent	22	88.00	95.65
Very Good	1	4.00	4.35
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	23	92.00	100.00
Total Missing	2	8.00	
Total	25	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brenda Blyler, MSN, CRNP (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	14	56.00	66.67
Very Good	7	28.00	33.33
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	21	84.00	100.00
Total Missing	4	16.00	
Total	25	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? William Matthai, Jr., MD (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	18	72.00	94.74
Very Good	1	4.00	5.26
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	19	76.00	100.00
Total Missing	6	24.00	
Total	25	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	17	68.00	68.00
Location/ease of access	18	72.00	72.00
Faculty	3	12.00	12.00
Earn CME credits	21	84.00	84.00
Total Valid	25	100.00	100.00



Future CE activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	11	44.00	45.83
Agree	9	36.00	37.50
Neutral	4	16.00	16.67
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	24	96.00	100.00
Total Missing	1	4.00	
Total	25	100.00	



What is your professional degree?

Comment
PhD

What is your specialty?

Comment
General Surgery
Research
Peds
Allergy/Asthma
Allergy/Asthma
Urgent Care

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
To treat and evaluate and diagnose patients with osteoporosis and diabetes
Apply to new and established patient
More confidence in treating diabetics with new drug therapies
Acceptable options of care and treatment
Apply CHADS2 to AF patients
Able to teach patients better about compliance to various therapies presented
Lab testing with IBD/Crohn's/UC
How to use FRAX
I am going to review current treatments and check each new protocol
Treatment for psoriasis and management of patients taking opioids
Appropriate pre-testing and starting biologicals for psoriasis. Opioid conversion
Utilizing the FRAX calculation
CHADS2 and opioid management
Using FRAX and CHADS2
Increase use of FRAX
CHADS2 score
I will order more Dexa scans and FRAX score
Osteoporosis screening

What topics would you like to see offered as CE activities in the future?

Comment
Hypertension and depression
HTN and RA/OA
Contraceptive management and dermatology issues
Asthma
Mood disorders and evaluation of ADD/ADHD and med adjustments
MS overview and treatment and HTN management
Cardio/Mental Health and Women's Health
Adrenal fatigue
Women's Health
Refractory HTN and headache management
Heart failure
Fibromyalgia
More dermatology/CHF/Asthma/COPD
HTN
Rheumatology and dermatology topics
Lyme disease and insulin therapies for management of diabetes and depression

Additional comments:

Comment
Good program overall
Topics were all very relevant
Thank you
Excellent-first time attendee and will let co-workers know about future lectures and will come next year
Great information
Diabetes lecture was informative
Excellent speakers
Great conference
As a new graduate I found this course a good educational experience. Staff was very friendly and helpful
Very good
Please offer this again next year

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	3.36	2.96	1.00	1.08	1.21	1.17	1.32
Variance	0.24	10.29	0.00	0.08	0.17	0.15	0.23
Standard Deviation	0.49	3.21	0.00	0.28	0.41	0.39	0.48
Standard Error	0.10	0.64	0.00	0.06	0.08	0.08	0.10
Minimum	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	4.00	8.00	1.00	2.00	2.00	2.00	2.00
Median	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	7.00	0.00	1.00	1.00	1.00	1.00

	Learning Objectives6	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care	Make Changes	Implement New Strategies
Mean	1.00	1.46	1.46	1.42	1.46	1.61	1.70
Variance	0.00	0.26	0.26	0.25	0.26	0.79	1.13
Standard Deviation	0.00	0.51	0.51	0.50	0.51	0.89	1.06
Standard Error	0.00	0.10	0.10	0.10	0.10	0.19	0.22
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	1.00	2.00	2.00	2.00	2.00	4.00	4.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	0.00	1.00	1.00	1.00	1.00	3.00	3.00

	Sandra Hall Kesner CNP {Osteo}	Brad P Glick DO {Psoriasis}	Mark Osterman MD {IBD}	Carol P Curtiss MSN {Opioids}	Brenda Blyler MSN {Diabetes}	William Matthai Jr MD {AFib}	Sandra Hall Kesner CNP {Osteo} Bias
Mean	4.87	4.48	4.65	4.83	3.37	4.81	4.96
Variance	0.12	0.99	0.33	0.24	1.02	0.16	0.04
Standard Deviation	0.34	0.99	0.57	0.49	1.01	0.40	0.21
Standard Error	0.07	0.21	0.12	0.10	0.23	0.10	0.04
Minimum	4.00	1.00	3.00	3.00	2.00	4.00	4.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	3.00	5.00	5.00
Range	1.00	4.00	2.00	2.00	3.00	1.00	1.00

	Brad P Glick DO {Psoriasis} Bias	Mark Osterman MD {IBD} Bias	Carol P Curtiss MSN {Opioids} Bias	Brenda Blyler MSN {Diabetes} Bias	William Matthai Jr MD {AFib} Bias	Reasons for Participating	Future CE Activities
Mean	4.87	4.91	4.96	4.67	4.95	-	1.71
Variance	0.12	0.08	0.04	0.23	0.05	-	0.56
Standard Deviation	0.34	0.29	0.21	0.48	0.23	-	0.75
Standard Error	0.07	0.06	0.04	0.11	0.05	-	0.15
Minimum	4.00	4.00	4.00	4.00	4.00	-	1.00
Maximum	5.00	5.00	5.00	5.00	5.00	-	3.00
Median	5.00	5.00	5.00	5.00	5.00	-	2.00
Range	1.00	1.00	1.00	1.00	1.00	-	2.00